Biblio

Author Title [ Type(Asc)] Year
Filters: Author is Hu, Jiong  [Clear All Filters]
Journal Article
Wang L, Wang Y, Tang W, Dou H-B, Shan J-H, Hu J. The superiority of allogeneic hematopoietic stem cell transplantation from unrelated donor over chemotherapy for adult patients with high-risk acute lymphoblastic leukemia in first remission. Int J Hematol. 2013.
Wang L, Xu G, Wang L, Jiang J, Gao W, Wan M, Blaise D, Hu J. Post-transplant cyclophosphamide at 80 mg/kg with low dose post-engraftment anti-thymocyte globulin in haploidentical transplantation with myeloablative conditioning. Bone Marrow Transplant. 2024.
Sun Y, Huang J, Hao C, Li Z, Liang W, Zhang W, Chen B, Yang W, Hu J. Population pharmacokinetic analysis of intravenous busulfan: GSTA1 genotype is not a predictive factor of initial dose in Chinese adult patients undergoing hematopoietic stem cell transplantation. Cancer Chemother Pharmacol. 2019.
Li X, Dong Y, Li Y, Ren R, Wu W, Zhu H, Zhang Y, Hu J, Li J. Low-dose decitabine priming with intermediate-dose cytarabine followed by umbilical cord blood infusion as consolidation therapy for elderly patients with acute myeloid leukemia: a phase II single-arm study. BMC Cancer. 2019;19(1):819.
Jiang J-L, Gao W-H, Wang L-N, Wan M, Wang L, Hu J. Low incidence of relapse with moderate conditioning regimen of fludarabine, busulfan and melphalan for patients with myeloid malignancies: a single-center analysis of 100 patients. Transplant Cell Ther. 2023.
Gao L, Zhang Y, Wang S, Kong P, Su Y, Hu J, Jiang M, Bai H, Lang T, Wang J, et al. Effect of rhG-CSF Combined With Decitabine Prophylaxis on Relapse of Patients With High-Risk MRD-Negative AML After HSCT: An Open-Label, Multicenter, Randomized Controlled Trial. J Clin Oncol. 2020:JCO1903277.
Long J, Chen X, Shen Y, Lei Y, Mu L, Wang Z, Xiang R, Gao W, Wang L, Wang L, et al. A combinatorial therapeutic approach to enhance FLT3-ITD AML treatment. Cell Rep Med. 2023:101286.
Qian J-J, Hu X, Wang Y, Zhang Y, Du J, Yang M, Tong H, Bin Qian W-, Wei J, Yu W, et al. CAG regimen for refractory or relapsed adult T-cell acute lymphoblastic leukemia: A retrospective, multicenter, cohort study. Cancer Med. 2020.